Dr Jenny Shannon

Clinical Senior Lecturer
Medicine, Nepean Clinical School

Telephone +61 2 4734 3500

Map

Selected grants

2013

  • Improving patient outcomes for patients with Gastrointestinal (GI) cancer through clinical trials research: An application on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG); Goldstein D, Simes R, Abdi E, Ackland S, Pavlakis N, Shannon J; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2009

  • Phase III Study in patients with Locally Advanced Pancreatic cancer: Gemcitabine +/- chemoradiotherapy and +/- erlotinib; Goldstein D, Shannon J, Spry N, Padbury R, Shannon J, Biankin A, Kneebone A, FitzGerald P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2007

  • Phase II study of chemotherapy and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer; Shannon J, Goldstein D, Shannon J, Lipton L, Ackland S, Karapetis C, Van Hazel G; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Greenhalf, W., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Lamb, R., Garner, E., Campbell, F., Mackey, J., Costello, E., Shannon, J., et al (2014). Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. National Cancer Institute. Journal, 106(1), 1-10. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]
  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]
  • Shannon, J. (2006). Traffic fine. The Lancet, 367(9520), 1456-7. [More Information]

2014

  • Greenhalf, W., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Lamb, R., Garner, E., Campbell, F., Mackey, J., Costello, E., Shannon, J., et al (2014). Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. National Cancer Institute. Journal, 106(1), 1-10. [More Information]

2011

  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]

2009

  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]

2008

  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]

2006

To update your profile click here. For support on your academic profile contact .